HUTCHMED Announces US$608 million Divestment of Non-Core
6 days ago · Investor Enquiries +852 2121 8200 / [email protected] Media Enquiries FTI Consulting – +44 20 3727 1030 / [email protected] Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 ...
News & Presentations - HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
HUTCHMED to divest 45% equity interest in SHPL for $608m
4 days ago · HUTCHMED (China) has agreed to sell a 45% equity interest in the non-core, non-consolidated joint venture (JV) Shanghai Hutchison Pharmaceuticals (SHPL) for $608m to GP Health Service Capital and ...
HUTCHMED Announces US$608 million Divestment of Non-Core …
6 days ago · — Focused R&D investment includes HUTCHMED’s proprietary antibody-targeted therapy conjugate platform, with first candidates expected to enter clinical trials in the second half of 2025 —
HUTCHMED Announces US$608 million Divestment of Non-Core …
6 days ago · HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted ...
NMPA grants priority review for HUTCHMED’s NSCLC combo
4 days ago · HUTCHMED is now set to gain a milestone payment from AstraZeneca. Progression-free survival (PFS) was the primary endpoint as evaluated by investigators. Secondary endpoints include PFS by independent review, and overall survival. ... Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.
Hutchmed announces progress, hits milestone with lung cancer …
4 days ago · Hutchmed China announced a number of advancements on Thursday, ... Josh White Sharecast News . 02 Jan, 2025 15:30 02 Jan, 2025 15:03. Hutchmed announces progress, hits milestone with lung cancer ...
Billionaire Li Ka-shing’s Hutchmed in $608 million health unit …
5 days ago · Jan 1 (Reuters) - Hutchmed (China)(0013.HK), opens new tab, controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship ...
News & Press Releases - HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Takeda and HUTCHMED Announce Marketing Authorization …
Jun 15, 2023 · HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.